Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Suboxone Stories

2014-04-07 12:32:56

First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., April 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45(th) Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. Four abstracts will be presented highlighting data from the clinical development...

2014-03-14 23:01:23

Suboxone has become a popular medication to use in detox from alcohol and other opiate addictions. Lake Worth, FL (PRWEB) March 14, 2014 When medically necessary, Millennium Treatment Group has begun prescribing Suboxone therapy to Millennium patients in a properly certified medical facility using DCF approved protocols. Suboxone is an opiod blocker medication that has been proven to reduce the negative side effects of withdrawal and ease the discomfort of going cold turkey. Millennium...

2014-03-04 12:26:45

The death of actor Philip Seymour Hoffman from a heroin overdose has generated discussion regarding medical treatment to prevent heroin deaths. Suboxone (Buprenorphine/Naloxone) is a medication that is used to treat addiction to heroin and other narcotic painkillers. NEW YORK, March 4, 2014 /PRNewswire/ -- The death of actor Philip Seymour Hoffman from a heroin overdose has generated discussion regarding medical treatment to prevent heroin deaths. Buprenorphine is a medication used...

2014-01-30 08:30:48

First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., Jan. 30, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that data from clinical studies of BUNAVAIL have been accepted for presentation at the American Society of Addiction Medicine (ASAM) 45(th) Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. (Logo:...

2013-10-08 16:25:14

DUBLIN, Oct. 8, 2013 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Sublingual Film 2 mg/0.5 mg and 8 mg/2 mg. Actavis' ANDA product is a generic version of Reckitt Benckiser's Suboxone(®) Sublingual Film, which is indicated for maintenance treatment of opioid dependence. Reckitt...

2013-09-10 08:26:24

New Public Health Initiative Helps Reveal the Real Situation About Growing National Epidemic RICHMOND, Va., Sept. 10, 2013 /PRNewswire/ -- Michael "The Situation" Sorrentino today helped launch a new public health initiative titled "Reset Reality" designed to increase knowledge and understanding of the prevalence, science and treatment of opioid prescription painkiller addiction - a condition he personally struggled with until finally seeking help in 2012. Working in partnership...

2013-02-25 04:21:54

RICHMOND, Va., Feb. 25, 2013 /PRNewswire/ -- Reckitt Benckiser Pharmaceuticals Inc. (RBP) announces that the U.S. Food and Drug Administration (FDA) has denied a Citizen's Petition filed by the Company. In the Citizen's Petition, RBP presented a new evaluation of pediatric exposure data and recommended that the FDA adopt more stringent packaging standards and increased educational interventions to help reduce the number of children exposed to buprenorphine-containing products...

2013-02-13 23:02:01

Five Points Wellness and Recovery: A 12-Month Bio-Psycho-Social Intensive Outpatient Treatment Program Utilizing Suboxone, Psychotherapy, Wellness and Occupational Support Mequon, Wisconsin (PRWEB) February 13, 2013 Each day millions of people suffer from the devastating cycle of opiate addiction. The impact of opiate addiction extends far beyond the ravages on the body. The ramifications of opiate addiction causes job loss, failed relationships, a disregard for one´s physical...

2012-09-25 06:27:08

RICHMOND, Va., Sept. 25, 2012 /PRNewswire/ - Reckitt Benckiser Pharmaceuticals Inc. issued a Citizen Petition today to request the U.S. Food and Drug Administration (FDA) to require all manufacturers of buprenorphine-containing products for the treatment of opioid dependence to implement national public health safeguards involving pediatric exposure educational campaigns and child resistant, unit-dosed packaging to reduce the risk of pediatric exposure. The company has had in place an...

2012-09-13 02:27:07

RALEIGH, N.C., Sept. 13, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced a positive outcome of the Company's pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX), which is being developed for the potential treatment of opioid dependence and utilizes the patented BioErodible MucoAdhesive (BEMA) technology to deliver buprenorphine combined with the opioid antagonist naloxone. Based on the positive outcome of this study, BDSI continues to...